Grupo de Investigación en Fisiopatología Cardiovascular
CTS237
Hospital Universitario Virgen de las Nieves
Granada, EspañaPublications in collaboration with researchers from Hospital Universitario Virgen de las Nieves (16)
2024
2022
2021
2019
-
Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years
Scientific Reports, Vol. 9, Núm. 1
-
DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients
Medicine (United States), Vol. 98, Núm. 32
-
Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients
AIDS, Vol. 33, Núm. 2, pp. 269-278
-
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort
PLoS ONE, Vol. 14, Núm. 8
2018
-
Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry
Journal of Thrombosis and Thrombolysis, Vol. 46, Núm. 4, pp. 551-558
-
Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients
AIDS, Vol. 32, Núm. 11, pp. 1423-1430
2017
-
Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494
2016
2015
-
Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 11, pp. 2247-2255
2014
2009
-
Prevalencia de enfermedad arterial periférica asintomática en pacientes con ictus isquémico no cardioembólico
Neurologia, Vol. 24, Núm. 6, pp. 366-372
2005
-
Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma
Cancer Chemotherapy and Pharmacology, Vol. 55, Núm. 2, pp. 197-202
2004
-
Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: Results of a large, multicentre phase II study
Cancer Chemotherapy and Pharmacology, Vol. 53, Núm. 1, pp. 75-81